Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Irhythm Technologies Inc (NQ: IRTC )

73.99 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4
Open 73.99
Bid (Size) 29.74 (1)
Ask (Size) 117.64 (1)
Prev. Close 73.99
Today's Range 73.99 - 73.99
52wk Range 55.92 - 124.11
Shares Outstanding 29,403,360
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
iRhythm Technologies to Participate in the Citi 2024 Global Healthcare Conference
From iRhythm
Via GlobeNewswire
iRhythm Data Presented at the American Heart Association 2024 Scientific Sessions Reinforce Clinical and Health Economic Value of Zio Long-Term Continuous Monitoring
Five new studies span three focus areas for LTCM devices: digital engagement and patient satisfaction, arrhythmia patterns during sleep and activity, and the potential health care resource and economic... 
From iRhythm
Via GlobeNewswire

Performance

YTD
-26.99%
-26.99%
1 Month
-2.23%
-2.23%
3 Month
+5.99%
+5.99%
6 Month
-15.70%
-15.70%
1 Year
-16.20%
-16.20%

More News

Read More
iRhythm Technologies to Participate in the Wolfe Research 2024 Healthcare Conference
From iRhythm
Via GlobeNewswire
Forecasting The Future: 6 Analyst Projections For iRhythm Technologies
Via Benzinga
Earnings Preview For iRhythm Technologies
Via Benzinga
IRHYTHM ALERT: Bragar Eagel & Squire, P.C. is Investigating iRhythm Technologies, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifications to Its Zio® AT Device
From iRhythm
Via GlobeNewswire
iRhythm Technologies Announces Third Quarter 2024 Financial Results
From iRhythm
Via GlobeNewswire
Beyond The Numbers: 9 Analysts Discuss iRhythm Technologies Stock
Via Benzinga
Key Takeaways From iRhythm Technologies Analyst Ratings
Via Benzinga
Newly Published Research Shows 14-Day Monitoring Detected Almost Three Times More Nonsustained Ventricular Tachycardia Than Standard 48-Hour Monitoring in Patients with Hypertrophic Cardiomyopathy
From iRhythm
Via GlobeNewswire
Trump Media & Tech, ImmunityBio, And iRhythm Are Among Top 10 Mid Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio?
Via Benzinga
Topics Government
Exposures Political
IRHYTHM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of iRhythm Technologies, Inc. - IRTC
From Kahn Swick & Foti, LLC
Via Business Wire
Nasdaq Turns Higher; Verizon Shares Fall After Q3 Results
Via Benzinga
With FDA Approval iRhythm May Be Able To Lift Regulatory Overhang, Investor Skepticism, Analyst Says
Via Benzinga
Exposures Product Safety
Crude Oil Rises Sharply; 3M Posts Upbeat Earnings
Via Benzinga
Exposures Fossil Fuels
Quest Diagnostics Posts Upbeat Results, Joins GM, Philip Morris And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
iRhythm Technologies Receives FDA 510(k) Clearance for Design Updates Previously Made to Its Zio® AT Device
From iRhythm
Via GlobeNewswire
iRhythm Technologies to Report Third Quarter 2024 Financial Results on October 30, 2024
From iRhythm
Via GlobeNewswire
IRHYTHM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of iRhythm Technologies, Inc. - IRTC
From Kahn Swick & Foti, LLC
Via Business Wire
iRhythm Technologies Announces Japanese Regulatory Approval of the Zio® ECG Monitoring System, the First Product to Deliver Arrhythmia Monitoring Service Utilizing Artificial Intelligence
From iRhythm
Via GlobeNewswire
iRhythm Unveils Data Demonstrating Superior Real-World Performance of Next-Generation Zio® Monitor at HRX 2024 Meeting
From iRhythm
Via GlobeNewswire
iRhythm Technologies Enters License Agreement with BioIntelliSense for Multiparameter Sensor Technology to be Used in Ambulatory Cardiac Monitoring
From iRhythm
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.